Metallothionein-2: An emerging target in inflammatory diseases and cancers
Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strat...
Gespeichert in:
| Veröffentlicht in: | Pharmacology & therapeutics (Oxford) 2023-04, Vol.244, p.108374-108374, Article 108374 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108374 |
|---|---|
| container_issue | |
| container_start_page | 108374 |
| container_title | Pharmacology & therapeutics (Oxford) |
| container_volume | 244 |
| creator | Wang, Xue-Ling Schnoor, Michael Yin, Lei-Miao |
| description | Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strategies have been developed to inhibit or modify MT-2, revealing its potential as drug target in diseases. Therefore, a better understanding of the mechanisms of MT-2 action is warranted to improve drug development for potential clinical applications. In this review, we highlight recent advances in determining the protein structure, regulation, binding partners, and new functions of MT-2 in inflammatory diseases and cancers. |
| doi_str_mv | 10.1016/j.pharmthera.2023.108374 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2785197142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0163725823000384</els_id><sourcerecordid>2785197142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-a2f4f9a7fe87e4a3de589455d158fbf022b90f9e87c264820b5a4377cc71fd093</originalsourceid><addsrcrecordid>eNqFkMtKAzEUQIMotlZ_QWbpZmqSyTQZd7X4pOJGwV1IMzdtykymJqnQvzdlqi6FwIXcc18HoYzgMcFkcr0eb1bKt3EFXo0ppkX6FgVnR2hIBK_yxHwco2EKRc5pKQboLIQ1xpgxTE_RoJgIUTFGhuj5BaJqmi6ubOfAupzeZFOXQQt-ad0yi8ovIWbWpWca1bYqdn6X1TaAChAy5epMK6fBh3N0YlQT4OIQR-j9_u5t9pjPXx-eZtN5rtOGMVfUMFMpbkBwYKqooUy7lGVNSmEWBlO6qLCpUlbTCRMUL0rFCs615sTUuCpG6Krvu_Hd5xZClK0NGppGOei2QVIuSlJxwmhCRY9q34XgwciNt63yO0mw3JuUa_lnUu5Nyt5kKr08TNkuWqh_C3_UJeC2ByDd-mXBy6AtJBO19aCjrDv7_5RvQeyJ8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785197142</pqid></control><display><type>article</type><title>Metallothionein-2: An emerging target in inflammatory diseases and cancers</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Wang, Xue-Ling ; Schnoor, Michael ; Yin, Lei-Miao</creator><creatorcontrib>Wang, Xue-Ling ; Schnoor, Michael ; Yin, Lei-Miao</creatorcontrib><description>Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strategies have been developed to inhibit or modify MT-2, revealing its potential as drug target in diseases. Therefore, a better understanding of the mechanisms of MT-2 action is warranted to improve drug development for potential clinical applications. In this review, we highlight recent advances in determining the protein structure, regulation, binding partners, and new functions of MT-2 in inflammatory diseases and cancers.</description><identifier>ISSN: 0163-7258</identifier><identifier>EISSN: 1879-016X</identifier><identifier>DOI: 10.1016/j.pharmthera.2023.108374</identifier><identifier>PMID: 36889441</identifier><language>eng</language><publisher>England: Elsevier Inc</publisher><subject>Cadmium - metabolism ; Cancer ; Drug resistance ; Humans ; Inflammatory disease ; Metallothionein - metabolism ; Metallothionein-2 ; Neoplasms - drug therapy ; Nuclear factor erythroid 2-related factor 2 ; Transgelin-2 ; Zinc - metabolism</subject><ispartof>Pharmacology & therapeutics (Oxford), 2023-04, Vol.244, p.108374-108374, Article 108374</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-a2f4f9a7fe87e4a3de589455d158fbf022b90f9e87c264820b5a4377cc71fd093</citedby><cites>FETCH-LOGICAL-c374t-a2f4f9a7fe87e4a3de589455d158fbf022b90f9e87c264820b5a4377cc71fd093</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.pharmthera.2023.108374$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27907,27908,45978</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36889441$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xue-Ling</creatorcontrib><creatorcontrib>Schnoor, Michael</creatorcontrib><creatorcontrib>Yin, Lei-Miao</creatorcontrib><title>Metallothionein-2: An emerging target in inflammatory diseases and cancers</title><title>Pharmacology & therapeutics (Oxford)</title><addtitle>Pharmacol Ther</addtitle><description>Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strategies have been developed to inhibit or modify MT-2, revealing its potential as drug target in diseases. Therefore, a better understanding of the mechanisms of MT-2 action is warranted to improve drug development for potential clinical applications. In this review, we highlight recent advances in determining the protein structure, regulation, binding partners, and new functions of MT-2 in inflammatory diseases and cancers.</description><subject>Cadmium - metabolism</subject><subject>Cancer</subject><subject>Drug resistance</subject><subject>Humans</subject><subject>Inflammatory disease</subject><subject>Metallothionein - metabolism</subject><subject>Metallothionein-2</subject><subject>Neoplasms - drug therapy</subject><subject>Nuclear factor erythroid 2-related factor 2</subject><subject>Transgelin-2</subject><subject>Zinc - metabolism</subject><issn>0163-7258</issn><issn>1879-016X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMtKAzEUQIMotlZ_QWbpZmqSyTQZd7X4pOJGwV1IMzdtykymJqnQvzdlqi6FwIXcc18HoYzgMcFkcr0eb1bKt3EFXo0ppkX6FgVnR2hIBK_yxHwco2EKRc5pKQboLIQ1xpgxTE_RoJgIUTFGhuj5BaJqmi6ubOfAupzeZFOXQQt-ad0yi8ovIWbWpWca1bYqdn6X1TaAChAy5epMK6fBh3N0YlQT4OIQR-j9_u5t9pjPXx-eZtN5rtOGMVfUMFMpbkBwYKqooUy7lGVNSmEWBlO6qLCpUlbTCRMUL0rFCs615sTUuCpG6Krvu_Hd5xZClK0NGppGOei2QVIuSlJxwmhCRY9q34XgwciNt63yO0mw3JuUa_lnUu5Nyt5kKr08TNkuWqh_C3_UJeC2ByDd-mXBy6AtJBO19aCjrDv7_5RvQeyJ8w</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Wang, Xue-Ling</creator><creator>Schnoor, Michael</creator><creator>Yin, Lei-Miao</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202304</creationdate><title>Metallothionein-2: An emerging target in inflammatory diseases and cancers</title><author>Wang, Xue-Ling ; Schnoor, Michael ; Yin, Lei-Miao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-a2f4f9a7fe87e4a3de589455d158fbf022b90f9e87c264820b5a4377cc71fd093</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cadmium - metabolism</topic><topic>Cancer</topic><topic>Drug resistance</topic><topic>Humans</topic><topic>Inflammatory disease</topic><topic>Metallothionein - metabolism</topic><topic>Metallothionein-2</topic><topic>Neoplasms - drug therapy</topic><topic>Nuclear factor erythroid 2-related factor 2</topic><topic>Transgelin-2</topic><topic>Zinc - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xue-Ling</creatorcontrib><creatorcontrib>Schnoor, Michael</creatorcontrib><creatorcontrib>Yin, Lei-Miao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacology & therapeutics (Oxford)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xue-Ling</au><au>Schnoor, Michael</au><au>Yin, Lei-Miao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metallothionein-2: An emerging target in inflammatory diseases and cancers</atitle><jtitle>Pharmacology & therapeutics (Oxford)</jtitle><addtitle>Pharmacol Ther</addtitle><date>2023-04</date><risdate>2023</risdate><volume>244</volume><spage>108374</spage><epage>108374</epage><pages>108374-108374</pages><artnum>108374</artnum><issn>0163-7258</issn><eissn>1879-016X</eissn><abstract>Metallothionein-2 (MT-2) was originally discovered as a mediator of zinc homeostasis and cadmium detoxification. However, MT-2 has recently received increased attention because altered expression of MT-2 is closely related to various diseases such as asthma and cancers. Several pharmacological strategies have been developed to inhibit or modify MT-2, revealing its potential as drug target in diseases. Therefore, a better understanding of the mechanisms of MT-2 action is warranted to improve drug development for potential clinical applications. In this review, we highlight recent advances in determining the protein structure, regulation, binding partners, and new functions of MT-2 in inflammatory diseases and cancers.</abstract><cop>England</cop><pub>Elsevier Inc</pub><pmid>36889441</pmid><doi>10.1016/j.pharmthera.2023.108374</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-7258 |
| ispartof | Pharmacology & therapeutics (Oxford), 2023-04, Vol.244, p.108374-108374, Article 108374 |
| issn | 0163-7258 1879-016X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2785197142 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | Cadmium - metabolism Cancer Drug resistance Humans Inflammatory disease Metallothionein - metabolism Metallothionein-2 Neoplasms - drug therapy Nuclear factor erythroid 2-related factor 2 Transgelin-2 Zinc - metabolism |
| title | Metallothionein-2: An emerging target in inflammatory diseases and cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T09%3A41%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metallothionein-2:%20An%20emerging%20target%20in%20inflammatory%20diseases%20and%20cancers&rft.jtitle=Pharmacology%20&%20therapeutics%20(Oxford)&rft.au=Wang,%20Xue-Ling&rft.date=2023-04&rft.volume=244&rft.spage=108374&rft.epage=108374&rft.pages=108374-108374&rft.artnum=108374&rft.issn=0163-7258&rft.eissn=1879-016X&rft_id=info:doi/10.1016/j.pharmthera.2023.108374&rft_dat=%3Cproquest_cross%3E2785197142%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785197142&rft_id=info:pmid/36889441&rft_els_id=S0163725823000384&rfr_iscdi=true |